Premium
Self‐Assembled Poly(butadiene)‐ b ‐poly(ethylene oxide) Polymersomes as Paclitaxel Carriers
Author(s) -
Li Shuliang,
Byrne Belinda,
Welsh JoEllen,
Palmer Andre F.
Publication year - 2007
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1021/bp060208
Subject(s) - polymersome , paclitaxel , ethylene oxide , micelle , copolymer , chemistry , vesicle , drug carrier , polymer chemistry , materials science , biophysics , polymer , drug delivery , organic chemistry , membrane , biochemistry , amphiphile , aqueous solution , chemotherapy , surgery , medicine , biology
In this work, self‐assembled poly(butadiene)‐ b ‐poly(ethylene oxide) (PB‐PEO) polymersomes (polymer vesicles) and worm micelles were evaluated as paclitaxel carriers. Paclitaxel was successfully incorporated into PB‐PEO polymersomes and worm micelles. The loading capacity of paclitaxel inside PB‐PEO colloids ranged from 6.7% to 13.7% w/w, depending on the morphology of copolymer colloids and the molecular weight of diblock copolymer. Paclitaxel loaded OB4 (PB 219 ‐PEO 121 ) polymersome formulations were colloidally stable for 4 months at 4 °C and exhibited slow steady release of paclitaxel over a 5 week period at 37 °C. Evaluation of the in vitro cytotoxicity of paclitaxel‐polymersome formulations showed that the ability of paclitaxel‐loaded polymersomes to inhibit proliferation of MCF‐7 human breast cancer cells was less compared to paclitaxel alone. By increasing the concentration of paclitaxel in polymersomes from 0.02 to 0.2 μg/mL, paclitaxel‐polymersome formulations showed comparable activity in inhibiting the growth of MCF‐7 cells. Taken together, these results demonstrate that paclitaxel‐polymersomes have desirable restrained release profile and exhibit long‐term stability.